Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases

Articles

LEXICON’s INPEFA: Entry of Another Drug for Hea...

Heart failure is a global pandemic that affects at least 26 million people globally and is becoming more common. Heart failure health expenditures are substantial and will rise considerably as the ...

Jun 05, 2023

antibody-drug-conjugates-adcs-in-oncology
Antibody-drug Conjugates in Oncology: An Overview of the Current and Future Treatment Landscape

Antibody-drug conjugates (ADCs) are becoming more prominent in the cancer treatment market. Antibody-drug conjugates are one of the most rapidly increasing anticancer treatments. This approach uses a mAb attached to a cytotoxic payload via a chemical linker that is directed towards a target antigen expressed on the...

Find More
Chronic Obstructive Pulmonary Disease (COPD) Market Outlook
ATS 2023 Updates: Dupixent – A Ray of Hope For Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD)

DUPIXENT has shown positive pivotal results for COPD, confirming the key role of IL-4 and IL-13 in type 2 inflammatory diseases. DUPIXENT has the potential to be the first biologic with unprecedented and paradigm-shifting clinical results to treat COPD, having demonstrated a statistically significant reduc...

Find More
ATS 2023 Updates: AD109’s Potential as the First Oral Medication for Obstructive Sleep Apnea (OSA)

Apnimed’s AD109 has the potential to be the first oral pharmaceutical drug that remedies both, the primary cause of OSA, nocturnal airway obstruction, and the daytime symptoms of OSA, such as fatigue. The dual mode of action of AD109 leads to upper airway dilatation as well as enhanced breathing and oxygen...

Find More

More Views & Analysis

anca-associated-vasculitis-treatment
ANCA-associated Vasculitis Treatment Market: Unraveling the Complexities

ANCA-associated vasculitis is a rare, life-threatening autoimmune disease with a relapsing nature. ANCA-Associated vasculitis comprises three autoimmune disorders, i.e. Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Eosinophilic Granulomatosis with Polyangiitis (EGPA). The global yearly...

Find More

parkinsons-disease-psychosis-treatment
What Lies Ahead For Parkinson’s Disease Psychosis Treatment Market?

The term “psychosis” defines a group of mental symptoms that occur when there has been a partial loss of contact with reality. A person’s thoughts and perceptions are distorted during a psychotic episode, and they could find it difficult to distinguish between tangible and intangible. Other signs include nonsensica...

Find More

Electronic Health Records (EHRs) Benefit and Challenges
From Paper to Pixels: The Advantages and Challenges of Electronic Health Record

In recent years, technological innovation has led to significant improvements in the healthcare delivery system. It has strengthened the efficiency of the organization and hospital and has enhanced the health outcome as well. Among various emerging technologies, Electronic Health Records (EHRs) is one of the much-a...

Find More

epkinly-approval-for-dlbcl-treatment
Abbvie-Genmab’s EPKINLY Approval for DLBCL Treatment: The First CD20XCD3 Bispecific Antibody

Abbvie-Genmab’s EPKINLY, the first CD20XCD3 Bispecific Antibody gets US approval for Relapsed/Refractory DLBCL treatment. Roche’s Glofitamab is expected to garner benefits in Europe first. Let's have a glimpse of evolving DLBCL treatment landscape in Relapsed/Refractory setting and if bi-specific as a class can be...

Find More

chondrosarcoma-treatment
Chondrosarcoma Treatment Market: Insight on Patient Burden and Inhibrx’s INBX-109 US Market Entry in 2026

Chondrosarcoma is a group of bone tumors made up of cells that make too much cartilage. As per DelveInsight analysis, the total incident cases of chondrosarcoma in the 7MM comprised approximately 2,331 cases in 2022 and are projected to increase during the forecasted period. Our estimates suggest that the United St...

Find More

Graves’ Ophthalmopathy Therapeutics Assessment
Graves’ Ophthalmopathy Treatment Market: A Billion-Dollar Opportunity For Pharma Companies

Graves’ ophthalmopathy, also known as thyroid-associated ophthalmopathy and thyroid eye disease, is the most frequent extrathyroidal manifestation of Graves’ disease. The majority of Graves’ ophthalmopathy cases are caused due to Graves’ disease, and only a small percentage of these patients arise from other euthyr...

Find More

Alopecia Areata (AA) is an autoimmune disorder that leads to hair loss on the scalp, face, and on ot.....

Find More

Metachromatic Leukodystrophy (MLD) is a rare hereditary disease characterized by the accumulation of.....

Find More

The first biosimilar was made available to patients in the United States six years ago in 2021. Thes.....

Find More

Intra-Tumoral Cancer Therapy refers to any therapy that is delivered in very close anatomical proxim.....

Find More

Toll-like receptors (TLR) 7 and 8 are functionally localized to endosomes and recognize specific RNA.....

Find More

Anorexia Nervosa (AN) is a psychological condition that is characterized by an abnormally low weight.....

Find More